Objective-Endothelial cells (ECs), pericytes, and vascular smooth muscle cells (vSMCs) are essential for vascular development, and their dysfunction causes multiple cardiovascular diseases. Primary vascular cells for research are, however, difficult to obtain. Human-induced pluripotent stem cells (hiPSCs) derived from somatic tissue are a renewable source of ECs and vSMCs; however, their use as disease models has been limited by low and inconsistent efficiencies of differentiation and the lack of phenotypic bioassays. Approach and Results-Here, we developed defined conditions for simultaneous derivation of ECs and pericytes with high efficiency from hiPSCs of different tissue origin. The protocol was equally efficient for all lines and human embryonic stem cells (hESCs). The ECs could undergo sequential passage and were phenotypically indistinguishable, exhibiting features of arterial-like embryonic ECs. Moreover, hiPSC-derived ECs formed an authentic vascular plexus when cocultured with hiPSC-derived pericytes. The coculture system recapitulated (1) major steps of vascular development including EC proliferation and primary plexus remodeling, and (2) EC-mediated maturation and acquisition of contractile vSMC phenotype by pericytes. In addition, hiPSC-derived ECs integrated into developing vasculature as xenografts in zebrafish. This contrasts with more widely used ECs from human umbilical vein, which form only unstable vasculature and were completely unable to integrate into zebrafish blood vessels. Conclusions-We demonstrate that vascular derivatives of hiPSC, such as ECs and pericytes, are fully functional and can be used to study defective endothelia-pericyte interactions in vitro for disease modeling and studies on tumor angiogenesis. (Arterioscler Thromb Vasc Biol. 2014;34:177-186.) 
H uman pluripotent stem cells (hPSCs) proliferate during long periods and can differentiate into many cell types of the body. Because they can be derived from any healthy individual or patient, they are an increasingly important source of human cells for tissue engineering, modeling human disease, drug discovery, and safety pharmacology. Efficient directed differentiation of hPSCs toward both vascular endothelial cells (ECs) and the adjacent mural cells (pericytes or mesenchymal stromal cells [MSCs] and vascular smooth muscle cells [vSMCs] ) that provide vessels with stability is however crucial for some of these applications. Moreover, vascular differentiation of hPSCs could reveal early steps in endothelial specification during human development and tumor angiogenesis and, as a result, lead to better understanding of mechanisms that cause vascular defects, underlie various cardiovascular diseases, and contribute to vascular invasion of tumors. Investigating the molecular signals driving differentiation, their timing and impact on vascular function are therefore important in a broader context than just vascular development.
In vivo ECs, pericytes, and vSMCs exhibit remarkable heterogeneity, with the cells of arterial, venous, and lymphatic vessels as well as tissue-specific vascular beds each showing distinct features. 1, 2 Unfortunately, it has been difficult to derive and maintain ECs with the relevant vascular bed identity and tissue specific characteristics in vitro. This is important because alterations in EC identity and defective communication between ECs and pericytes cause multiple vascular diseases. For example, various genetic vascular malformations such as hereditary hemorrhagic telangiectasia, cerebral cavernous malformations, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) are caused by mutations in either endothelial (hereditary hemorrhagic telangiectasia, cerebral cavernous malformations) or vSMC-specific (CADASIL) genes. [3] [4] [5] Furthermore, defective EC-pericyte interactions are a hallmark of tumor blood vessels. 6 The limited availability of primary human tissues, poor expansion of ECs in vitro, and a lack of appropriate vSMCs are major drawbacks toward better understanding of the mechanisms of different cardiovascular diseases and pathological angiogenesis.
Our goal here was to develop a protocol for differentiation of hPSCs toward vascular cell lineages that is applicable to any hPSC line and results in well-characterized, functional ECs, pericytes, and vSMCs. The protocol described is based on fully defined media and timed addition of growth factors to monolayer cultures and does not require an aggregation step (embryoid body [EB] formation). It results in efficient generation of ECs from both hESC and human-induced pluripotent stem cell (hiPSC; either derived from skin biopsy fibroblasts [Fib] or blood outgrowth ECs [BOECs]) lines. In addition, the protocol facilitates simultaneous derivation of both ECs and pericytes, which have the potential to differentiate to more contractile vSMCs. On coculture, hiPSC-derived ECs and pericytes formed a vascular plexus in vitro that was responsive to transforming growth factor β (TGFβ) and NOTCH signaling. Moreover, ECs from all hPSC types exhibited similar phenotypes and developed a remarkable degree of functionality not only in a vascular plexus model in vitro but also in an organotypic transplantation model in vivo in zebrafish. hPSC-derived ECs performed significantly better in both functional assays compared with more widely used human umbilical vein ECs (HUVECs). The study thus provides human models of ECs and functional vessels in culture with high utility and opportunities for creating disease phenotypes in the vascular system resulting from specific gene mutations in ECs, pericytes, or vSMCs.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Mesoderm Induction and Vascular Specification of hPSCs in Monolayer
To induce mesoderm differentiation in hPSCs, we used defined medium based on the previously published bovine serum albumin (BSA) polyvinylalchohol essential lipids protocol. 7 The mesoderm differentiation protocol was optimized based on cardiac mesoderm induction from hPSCs, 8 and vascular specification conditions found to be effective in a forced aggregation SpinEB protocol (Orlova, unpublished). A schematic representation of the final protocol is shown in Figure  I in the online-only Data Supplement. We first tested combinations of the following growth factors from day 0 to 3 of differentiation: bone morphogenetic protein 4 (B; 30 ng/mL), vascular endothelial growth factor (VEGF; V; 50 ng/mL) in the presence of GSK3-kinase inhibitor (CHIR99021; CHIR, C; 1.5 µmol/L; BVC), or the same conditions with additional Activin A (ActA, A; 25 ng/mL; BVAC). The cultures were then refreshed on day 3 with bovine serum albumin (BSA) polyvinylalchohol essential lipids containing VEGF or VEGF and SB431542 (SB), selective TGF β type I receptor kinase inhibitor, at 5 μmol/L. Examination of cell surface expression of the hematoendothelial-specific marker (CD34) and CD31 or the cardiovascular marker Kinase insert Domain Receptor (KDR; also known as VEGFR2) by flow cytometry demonstrated robust induction of expression by day 10 ( Figure 1A ) with either protocol in the hiPSC line shown. Interestingly, vascular endothelial (VE)-Cadherin (VEC) was the earliest marker that was upregulated ( Figure IIa in the online-only Data Supplement). The earliest ECs were observed at day 6 to 7 of differentiation based on the appearance of cells with cobblestone morphology (data not shown), which coincided with the appearance of nonhemogenic VEC+/CD73+ cells, as described previously. 9 However, the percentage of mature ECs identified as VEC+/CD73+ was the highest on day 10 of differentiation ( Figure IIb in the online-only Data Supplement). In addition, we investigated whether there was expression of the earliest human hematoendothelial surface marker CD43. 10 Flow cytometric analysis revealed the presence of ≤1% of CD43+ cells, with majority of the CD31+/CD34+/CD105+ cells being CD43 negative ( Figure IIa in the online-only Data Supplement). Notably, addition of Activin A on days 0 to 3 resulted in more robust and reproducible differentiation among a range of hiPSC lines ( Figure III in the online-only Data Supplement). In addition, supplementation with VEGF together with SB (10 μmol/L) resulted on average in a 30% increase in the yield of ECs, which was consistent among several cell lines tested and in line with findings by other groups. 11, 12 The defined differentiation conditions resulted in the generation of CD34+/KDR+ cells in a variety of hiPSC cell lines (on average 18±3%) we recently generated from both human adult skin fibroblasts (Fib-iPSC) and BOECs (BOECs-iPSC) as well as hESC (HESC-NL4). [13] [14] [15] To confirm efficient mesoderm induction, we examined the expression of various early mesoderm genes, as well as EC-specific genes ( Figure 1B ). Downregulation of pluripotent stem cell markers, such as OCT4 and NANOG by day 4 of differentiation, was followed by the induction of primitive streak/mesoderm lineage markers, such as Brachyury T and platelet-derived growth factor receptor (PDGFR)α, over the same time period. The early endothelial-specific transcription factor (ETV2) was also upregulated at day 4, followed by robust induction of endothelial-specific genes by day 10 of differentiation (activin receptor-like kinase 1, CD105, KDR). Interestingly, we also 
Isolation and Expansion of hPSC-Derived ECs
Flow cytometry analysis of different hPSC lines on day 10 of differentiation showed robust induction of a CD31+ EC population, as well as CD31-PDGFRβ+ mesenchymal cells ( Figure 2A ). The differentiation efficiency was similar and consistent among different hPSC lines tested also using this assay, with average percentages 10% to 30% of CD31+/ CD34+ cells, as well as ≈30% PDGFR β + mesenchymal cells ( Figure 2B and 2C). We additionally examined the expression of other EC and mesenchymal cell markers on the endothelial CD31+/CD34+ population as well as PDGFRβ+ cells. Importantly, CD31+/CD34+ cells expressed reproducible and comparable levels of other EC-specific markers (VE-Cadherin, KDR, CD73, and CD105) and were negative for PDGFRβ. By contrast, the CD31−/CD34− population strongly upregulated PDGFRβ. Interestingly, expression of other mesenchymal stem cell markers (CD105 and CD73) in the CD31−/CD34− population was not observed on day 10 of differentiation ( Figure 2D ). We considered CD31 as the most appropriate marker for positive selection of ECs because our differentiation protocol resulted in a large number of ECs, and not other CD31+ hematopoietic progenitors, as evidenced by flow cytometry analysis showing that all CD31+ cells expressed VEC and other endothelial-specific markers ( Figure 2D ).
The protocol facilitated isolation of ECs with average purities >95% after just 1 selection round ( Figure 3A ). This is particularly important for reproducible and specific functional and signal transduction studies in cell populations. Furthermore, ECs isolated from hESC, BOECs-iPSC, or Fib-iPSC cell lines expressed similar levels of endothelial-specific surface antigens such as CD31, CD34, VEC, CD73, and CD105 ( Figure 3A ). At the same time, these ECs lacked expression of hematopoietic markers CD43 and CD45, although CD14 expression was still detected at low levels, in agreement with previously published studies ( Figure IV in the online-only Data Supplement). 16 Immunofluorescent analysis revealed junctional localization of VEC and CD31, as well as prominent intracellular staining for von Willebrand factor ( Figure 3B ). Interestingly, hiPSC-derived ECs also exhibited heterogeneous expression of lymphatic associated markers lymphatic vessel endothelial hyaluronan receptor 1 ( Figure 3B ). hiPSC-derived ECs could be passaged ≥5× in EC-serum free medium with VEGF (30 ng/mL), basic fibroblast growth factor (20 ng/mL), and 1% bovine platelet poor plasma extract and cryopreserved using standard procedures (not shown). Gene expression analysis revealed on average 2-fold higher expression of pan-endothelial markers such as CD31, VEC, and KDR than in HUVEC or human aortic ECs ( Figure 3C ). Interestingly, hPSC-derived ECs expressed significantly higher levels of the arterial marker Ephrin-B2 compared with human umbilical artery endothelial cells although expression of another more prominent arterial-specific marker Hey2, previously identified by gene expression profiling of primary human ECs, 17 was lower compared with human umbilical artery endothelial cells. In addition, we observed lower levels of the venous marker CoupTFII although EphrinB4 levels were comparable with HUVEC. hiPSC-derived ECs also expressed lymphatic vessel endothelial hyaluronan receptor 1 and VEGFR3. No expression of the lymphatic specific markers Podoplanin and Prox1 was observed (data not shown).
ECs derived from BOECs-iPSC and Fib-iPSC readily formed cord-like structures in the Matrigel tube formation assay as early as 6 hours postseeding ( Figure Va in the onlineonly Data Supplement). Interestingly, the endothelial cords remained stable for ≤48 hours with prominent cord structures still evident ≤72 hours (data not shown). These results differ strikingly from HUVECs, where cord structures tend to regress rapidly after 24 hours both in our hands (unpublished) as well as in publications by other groups. 18 Measurement of the total tube length and area covered by endothelial sprouts showed comparable values for BOECs-iPSC and Fib-iPSCderived ECs ( Figure Vb 
Isolation and Expansion of hPSC-Derived Pericytes
Plating the CD31− fraction resulted in the expansion of a homogenous population of cells that expressed pericyte and MSC markers (PDGFRβ, CD146, NG2, CD73, CD44, CD105; Figure 4A ). In addition, supplementation of medium with 10% fetal bovine serum or fetal bovine serum plus the growth factors TGFβ3 (1 ng/mL) and platelet-derived growth factor-BB (2 ng/mL) for 4 days resulted in downregulation of PDGFRα and upregulation of early contractile SMC markers, such as smooth muscle (SM) 22 and Calponin (CNN1) as observed by real-time polymerase chain reaction gene expression ( Figure 4B ) and immunofluorescent staining ( Figure 4C ). However, we did not observe expression of the definitive SMC marker SM myosin heavy chain (SMMHC) by immunofluorescent staining (data not shown), and only slight upregulation was observed by real-time gene expression analysis in hESC-derived mesenchymal cells ( Figure 4B ). The serum-free conditions resulted in the generation of cells with a similar morphology to those obtained in serum-based media ( Figure VI in the online-only Data Supplement). Thus, we created a renewable source of pericytes/SMCs cell types that are the principle components of the vascular wall, from hPSCs simultaneously with ECs.
Modeling Endothelia-Pericyte Interactions in Cultured Vascular Plexus In Vitro
Next, we established a 2D coculture system in vitro consisting of hiPSC-derived ECs and pericytes ( Figure 5A ). The protocol was optimized and adapted to the BD Pathway 855 imaging system, based on a method initially described for the coculture of HUVECs and vSMCs. 19 On day 7 of coculture, hiPSCderived ECs had organized and formed sprouts on top of the mesenchymal cells, as evidenced by immunofluorescent staining with the EC-specific CD31 marker ( Figure 5B ).
Then, we examined the functionality of BOECs-iPSC and Fib-iPSC-derived ECs in the endothelia-pericyte coculture sprouting assay. Interestingly, both BOECs-iPSC-as well as Fib-iPSC-derived ECs formed well-organized sprouts at day 7 of coculture ( Figure VII in the online-only Data Supplement). The TGFβ signaling pathway is indispensible for the formation of stable vasculature because it is crucial for regulating EC proliferation, pericyte/vSMC function, and endothelia-pericyte interactions. 11,20-24 Therefore, we first determined whether TGFβ signaling is important for the formation of vascular sprouts in the cocultures of hiPSC-derived ECs and pericytes. Notably, the activin receptor-like kinase 5 inhibitor SB enhanced sprout formation and resulted in an increase in the total area covered by endothelial sprouts (Figure 5C ; Figure VII The TGFβ and NOTCH signaling pathways are known to play important roles in promoting differentiation and acquisition of the contractile phenotype by mural cells. [24] [25] [26] In addition, paracrine interactions between ECs and mural cells can result in the induction of higher amounts of local biologically active TGFβ and lead to mural cell differentiation. 27 Therefore, we examined the effect of the endothelia-pericyte coculture on the induction of the contractile SM marker SM22. Interestingly, confocal images of cultures stained with CD31 and SM22 showed SM22-positive pericytes in close proximity to CD31positive endothelial sprouts ( Figure 5B ). Addition of SB caused an increase in the area covered by SM22-positive cells, as well as an increase in SM22 mRNA expression levels ( Figure  5B and 5D; Figure IX in the online-only Data Supplement). Importantly, the effect of SB was blocked on addition of N-3,5difluorophenyl acetyl-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester, an inhibitor of NOTCH, on both SM22 mRNA and area covered by SM22-positive cells ( Figure 5B and 5D ; Figure  IXb and IXc in the online-only Data Supplement). Addition of N-3,5-difluorophenyl acetyl-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester also resulted in a decrease in the area covered by SM22-positive cells in basal coculture conditions. However, addition of SB and N-3,5-difluorophenyl acetyl-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester together had no effect on the expression of SM22 in pericytes/MSCs cultured without ECs ( Figure IXa and IXb in the online-only Data Supplement). Therefore, we conclude that SB regulates SM22 levels via NOTCH-dependent heterotypic cell-cell interactions. In summary, supplementation with SB results in increased EC proliferation, and an increase in the substrate surface area covered by ECs; this resulted in potentiation of heterotypic cell-cell contacts mediated by NOTCH. However, blocking the NOTCH pathway had no effect on the total areas covered by EC sprouts (Figure 5C ). To further strengthen our data, and to exclude the possibility that the increase of SM22 is via paracrine factors, we also performed experiments where EC-conditioned medium, with or without SB, was used. EC growth medium or EC-conditioned medium gave similar outcomes on SM22 expression on SB addition ( Figure X 
Vascular Competence of hPSC-Derived ECs in Zebrafish Xenograft Model
Next, we examined the engraftment potential of Fib-iPSC and BOECs-iPSC-derived ECs in vivo. Initially, hiPSC-derived ECs were injected into early stage blastula (265 out of 512 cells) stage embryos ( Figure 6A ). The CD31+ cells derived from either Fib-iPSC or BOECs-iPSC were highly proficient in forming vessel-type structures within the zebrafish embryo ( Figure 6B and 6C) . Importantly, zebrafish embryos developed normally, and no abnormalities or edema were observed ( Figure XI in the online-only Data Supplement). Examination of human-specific proliferation markers (Ki67; Figure XII in the online-only Data Supplement), as well as the apoptosis marker Caspase-3, ( Figure XIII in the online-only Data Supplement) revealed the presence of proliferative human EC, with few apoptotic ECs. To confirm that ECs retain their characteristics on injection into zebrafish, we performed immunofluorescent staining with a human specific antibody against platelet endothelial cell adhesion molecule-1 (huPECAM1). The entire vessel formed by the human ECs was also labeled with human specific antibody against platelet endothelial cell adhesion molecule-1 ( Figure XIV in the online-only Data Supplement).
The CD31− control cells did not form any vessel-type structures (data not shown). Furthermore, there was no significant difference in vessel formation between ECs from the Fib-iPSC or BOECs-iPSC. The length of the vessels formed within the yolk of 30 embryos in which vessels were located in the yolk was compared. There was no significant difference in vessel length when ECs were derived from either the Fib-iPSC or the BOECs-iPSC lines ( Figure 6F ).
Furthermore, when the hiPSC-derived ECs were injected into the blood stream of 48 hpf embryos, the CD31+ cells were capable of integrating into the vascular system that had already developed ( Figure 6D ). Interestingly, HUVECs did not integrate into the embryonic zebrafish vasculature at all but rather attached to the vessels or migrated throughout the embryo (Figure 6E and 6G) . Together, these observations demonstrated that hiPSC-derived ECs were able to integrate functionally into embryonic zebrafish vasculature.
Discussion
Several groups have described induction of ECs and pericytes from hPSC. However, most of the published protocols are based on serum-containing media or require coculture with stromal cell lines. [28] [29] [30] [31] [32] More recently published protocols on differentiation in defined media required EB formation or forced aggregation in which hPSC are centrifuged to form compact spheroids or spin EBs. [33] [34] [35] These protocols are efficient (on average 20% to 30% ECs in the differentiated cultures) but are more difficult to adapt for scaling up EC production. In addition, for the spin EB system, hPSC lines usually have to be adapted to single cell, enzymatic passaging in bulk culture from culture as colonies, which can be difficult BOECs-iPSC-ECs (in red) integrated within the major vascular structure of the zebrafish Tg(fli1:GFP; in green) embryos, whereas HUVEC integration was poor (in red). Representative images were taken at 5 dpi. F, Comparison of the length of vessels formed from Fib-IPSC-ECs and BOECs-iPSC-ECs. Thirty zebrafish were randomly selected, and the vessels within the yolk sac were measured using Leica software. There was no statistically significant difference between the groups. G, Comparison of BOECs-iPSC-ECs and HUVECs integration after 48 hpf implantation into the vessels located within the embryonic zebrafish. Representative images were taken at 5 dpi. HUVEC, n=117, BOECs-iPSC-ECs, n=115. B-E, Scale bar, 100 μm. B′ and C′, Scale bar, 20 μm. iPSC indicates induced pluripotent stem cell. and time consuming. 36 This also might not be convenient if working with the multiple diseased hiPSC lines at the same time. We also noticed rather high line-to-line variation in the spin EB system when using hiPSC (Orlova, unpublished).
The protocol developed here has high line-to-line reproducibility and is suitable for use on hPSCs growing in simple, feeder-free culture conditions, such as mTeSR1 medium on a Matrigel substrate. In addition, and in contrast to previously published protocols, it does not require the presence of stromal cells. 9, 35, 37 As far as we are aware, it is the first description of simultaneous derivation of ECs and pericytes from hPSC in defined conditions. hPSC-ECs exhibited a typical EC morphology and expressed distinctive EC markers such as CD31, VEC, and von Willebrand factor. Based on gene and protein expression of both arterial and venous markers, as well the presence of lymphatic endothelial markers such as lymphatic vessel endothelial hyaluronan receptor 1 and VEGFR3, we concluded that they resemble embryonic ECs. The question of whether hPSC-ECs can be matured further toward various endothelial subsets in vitro remains open and requires additional research. By contrast, hPSC-pericytes expressed common pericyte/MSCs markers, such as CD146, CD73, CD105, CD44, PDGFRβ, an NG2, and could differentiate further into more contractile SMCs in the presence of TGFβ and platelet-derived growth factor-BB; they also acquired expression of early contractile markers such as SM22 and CNN1.
We further tested the functionality of hPSC-derived ECs and pericytes in 2 assays: the first was based on coculture of ECs and pericytes in monolayer and facilitated study of primary vascular plexus formation by ECs, as well as endothelia-pericyte interactions. hiPSC-derived ECs formed well-organized vascular sprouts on top of mesenchymal cells. In contrast to HUVECs, hiPSC-derived ECs were highly sensitive to TGFβ. Interestingly, the activin receptor-like kinase 5 inhibitor SB significantly increased the number of endothelial sprouts. This was most likely because of the more immature embryoniclike phenotype of hiPSC-derived ECs because sensitivity to TGFβ-mediated growth inhibition is typical of embryonic ECs. 11, 20, 21 Furthermore, heterotypic cell-cell interactions, between ECs and pericytes, are known to promote acquisition of more contractile vSMC markers by pericytes. 24, 38 Unexpectedly, supplementation of the culture medium with SB increased the expression of the contractile SMC marker SM22 in pericytes in coculture. It has been shown previously that endothelium-derived TGFβ is a more potent inducer of SM maturation than the growth factor added exogenously. 27 Therefore, the observed effect is most likely because of increase of total number of ECs that resulted from loss of the growth inhibitory effect of endogenous TGFβ. In addition to TGFβ, Notch signaling has been shown to be important in heterotypic cell-cell interactions and promoting differentiation of SMCs. 25, [39] [40] [41] [42] In line with this, blocking NOTCH signaling prevented acquisition of SM22 by pericytes.
The second assay was based on a zebrafish xenograft model. Development of alternatives to mouse and in vitro models for disease modeling is of high importance for both basic and pharmacological/clinical research. Zebrafish has been widely used as a model for studying development, but they are also valuable for modeling human disease. [43] [44] [45] One of their foremost advantages is optical transparency. Because of the small size of the embryos, they can be imaged throughout development and as whole-mount preparations. Critically, this preserves both the mechanical and the molecular integrity of the embryo. Zebrafish embryos have also recently been useful for studying vasculogenesis. 46 We demonstrated that hPSCderived ECs were able to incorporate into developing as well as established vasculature. Notably, there was no functional difference between the Fib-iPSC-or BOECs-iPSC-derived vessels formed within the embryos. Both cell lines gave CD31+ differentiated vascular derivatives that were capable of forming vessel structures when injected at the blastula stage of development but in neither case did the CD31-derivatives integrate. Furthermore, these hiPSC-derived ECs performed much better than the widely used HUVEC cells. Our observation of hiPSC-derived ECs within the embryonic zebrafish illustrates a new method for confirming EC identity in vivo and represents a step forwards in validating hPSC-derived ECs as human vascular disease models.
In summary, we have developed an efficient protocol for differentiation of hPSCs toward ECs and pericytes. hPSC-ECs derived in this protocol (1) exhibited an embryonic-like phenotype, with mixed arterial/venous identity and expression of subsets of lymphatic EC markers; (2) displayed remarkable functionality in multiple in vitro assays, and functional characteristics were similar in ECs derived from hPSCs with different donor cell origin; (3) were able to integrate into host vasculature in a zebrafish xenograft model. hPSC-derived pericytes expressed typical pericyte/MSCs markers and acquired a contractile phenotype on exposure to exogenous TGFβ or coculture with ECs.
Vascular differentiation of hPSCs could reveal early steps in endothelial specification during human development and lead to better understanding of mechanisms that cause vascular defects and underlie different cardiovascular diseases. As importantly, our coculture model is capable of modeling specific properties of both ECs and pericytes/vSMCs as they form a bona fide vascular plexus that captures the cross-talk these cells would normally exhibit in vivo. This interaction model we have developed is quantifiable and mimics aspects of tumor vasculogenesis including expected responses to TGFβ. In the future, we expect that the generation of specific subsets of ECs will be useful in such cocultures for modeling human vascular diseases in vitro and for tissue engineering.
